ISTA Pharmaceuticals to Present at the 14th Annual Needham Growth Conference
IRVINE, CA -- (MARKET WIRE) -- 01/03/12 -- ISTA Pharmaceuticals, Inc. (ISTA) (NASDAQ: ISTA), today announced it will present at the 14th Annual Needham Growth Conference at 10:40 a.m. Eastern Time on January 12, 2012, in New York, NY. ISTA's Chief Financial Officer and Vice President Corporate Development Lauren Silvernail will provide an update on the Company's marketed products and clinical programs.
The presentation will be webcast. To access the live audio broadcast of the presentation, or the subsequent archived recording, log onto http://www.istavision.com/investors.html. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
In addition, the Company reminded investors of its previously announced 2012 Guidance and Pipeline Update Webcast/Conference Call scheduled for January 4, 2012 at 4:30 p.m. ET.
Webcast and Conference Call access:
Domestic dial-in: 866-270-6057
International dial-in: 617-213-8891
The webcast/conference call will be webcast live and archived on ISTA's website until February 1, 2012. To access the 24-hour audio replay, U.S. and Canadian participants may dial 1-888-286-8010; international participants may dial 1-617-801-6888. The access code for the replay is 75601206.
ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals, Inc. is a fast growing and the third largest branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The Company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. Headquartered in Irvine, California, ISTA generated revenues of $156.5 million in 2010. For additional information about ISTA, please visit the corporate website at www.istavision.com.
For Investor Relations: Lauren Silvernail 949-788-5302 firstname.lastname@example.org Jeanie Herbert 949-789-3159 email@example.com Kathy Galante Burns McClellan 212-213-0006 firstname.lastname@example.org For General Media: Justin Jackson Burns McClellan 212-213-0006 email@example.com
Source: ISTA Pharmaceuticals